Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...

The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...

Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...

The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ...

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...